Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GNPX
stocks logo

GNPX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
--
--
-19.500
-11.72%
--
--
-20.500
+455.56%
--
--
-21.000
-86%
Estimates Revision
The market is revising No Change the revenue expectations for Genprex, Inc. (GNPX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -70.81%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-70.81%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Genprex Inc (GNPX.O) is -0.05, compared to its 5-year average forward P/E of -2.92. For a more detailed relative valuation and DCF analysis to assess Genprex Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.92
Current PE
-0.05
Overvalued PE
1.16
Undervalued PE
-7.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.69
Current PS
0.00
Overvalued PS
3.39
Undervalued PS
-2.01
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GNPX News & Events

Events Timeline

(ET)
2025-11-24
07:09:41
Genprex Releases Findings from Acclaim-1 Phase 1 Trial of Reqorsa Gene Therapy
select
2025-11-19 (ET)
2025-11-19
07:08:08
Genprex Partners with Gabrail Cancer Center for Acclaim Clinical Trials 1 and 3
select
2025-11-18 (ET)
2025-11-18
07:16:52
Genprex Receives U.S. Patent for Reqorsa Gene Therapy in Cancer Treatment
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
07:50 AMBenzinga
Congressman Invests in Lesser-Known Small Cap Lift Truck Firm

  • Congressman's Stock Transactions: Rep. Tim Moore (R-N.C.) disclosed multiple stock purchases, including significant investments in Hyster-Yale Inc., totaling between $145,000 and $350,000, which has attracted social media attention.

  • Recent Trading Activity: Moore's recent trades included buying shares of Hyster-Yale on several occasions in November, following previous transactions in October and September, with no sales reported this time.

  • Market Impact: Following the news of Moore's purchases, Hyster-Yale's stock price surged from $28.12 to $35.03, raising questions about the implications of his trades, especially given the company's history with government contracts.

  • Additional Investments: Alongside Hyster-Yale, Moore also purchased shares in Genprex, a small clinical stage gene therapy company, marking one of the smallest stocks ever bought by a member of Congress, which is expected to draw further scrutiny.

[object Object]
Preview
9.0
11-19PRnewswire
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

  • New Clinical Trial Site: Genprex, Inc. has added Gabrail Cancer Center in Canton, Ohio, as a new site for its Acclaim-1 and Acclaim-3 clinical trials, aimed at expanding patient access to its Reqorsa® Gene Therapy for lung cancer.

  • FDA Fast Track Designation: Both Acclaim-1 and Acclaim-3 trials have received FDA Fast Track Designation, which is intended to expedite the development and review of therapies that address unmet medical needs.

  • Acclaim-1 Trial Details: The Acclaim-1 trial is a Phase 1/2 study evaluating Reqorsa in combination with AstraZeneca's Tagrisso for late-stage non-small cell lung cancer, with early results showing promising efficacy and tolerability.

  • Acclaim-3 Trial Details: The Acclaim-3 trial is a Phase 1/2 study assessing Reqorsa alongside Genentech's Tecentriq as maintenance therapy for extensive stage small cell lung cancer, with plans for interim analysis after enrolling 25 patients.

[object Object]
Preview
8.5
10-28Newsfilter
Genprex Unveils At-The-Market Registered Direct Offering of Up to $10 Million in Accordance with Nasdaq Regulations

  • Funding Announcement: Genprex, Inc. has entered into agreements to issue 377,780 shares of common stock at $9.00 per share, aiming for gross proceeds of approximately $3.4 million, with potential additional proceeds of $6.6 million from short-term warrants.

  • Use of Proceeds: The company plans to utilize the net proceeds from this offering for working capital and general corporate purposes, with the closing expected around October 29, 2025, pending customary conditions.

  • Company Overview: Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes to patients with limited treatment options.

  • Regulatory Compliance: The shares are being offered under a "shelf" registration statement, while the unregistered warrants are offered in a private placement, adhering to the Securities Act regulations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Genprex Inc (GNPX) stock price today?

The current price of GNPX is 3.35 USD — it has increased 18.37 % in the last trading day.

arrow icon

What is Genprex Inc (GNPX)'s business?

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

arrow icon

What is the price predicton of GNPX Stock?

Wall Street analysts forecast GNPX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNPX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Genprex Inc (GNPX)'s revenue for the last quarter?

Genprex Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Genprex Inc (GNPX)'s earnings per share (EPS) for the last quarter?

Genprex Inc. EPS for the last quarter amounts to -5.00 USD, decreased -91.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for Genprex Inc (GNPX)'s fundamentals?

The market is revising No Change the revenue expectations for Genprex, Inc. (GNPX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -70.81%.
arrow icon

How many employees does Genprex Inc (GNPX). have?

Genprex Inc (GNPX) has 15 emplpoyees as of December 05 2025.

arrow icon

What is Genprex Inc (GNPX) market cap?

Today GNPX has the market capitalization of 7.61M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free